华兰疫苗 (301207)
Hualan Biological Vaccine Inc.
K-Line Chart
No K-line data
Stock Details
1. Key Indicators
- Total Shares(W): 60102.75
- Circulating A-Shares(W): 60064.82
- Earnings Per Share(RMB): 0.2224
- Net Assets Per Share(RMB): 9.4419
- Operating Revenue(W RMB): 80598.69
- Total Profit(W RMB): 13762.80
- Net Profit Attributable to Parent(W RMB): 13230.86
- Net Profit Growth Rate(%): -50.51
- Weighted Return on Equity(%): 2.2000
- Operating Cash Flow Per Share(RMB): 0.3030
- Undistributed Profit Per Share(RMB): 3.2421
- Capital Reserve Per Share(RMB): 4.8775
2. Main Business
The main business covers:
- Research, production, and sales of human vaccines
3. Company Basic Information
- Company Name: Hualan Biological Vaccine Inc.
- Listing Date: 2022-02-18
- Industry: Pharmaceutical Manufacturing
- Address: No. A1-1, Hualan Avenue, Xinxiang City, Henan Province, China
- Website: www.hualanbacterin.com
- Company Profile: The issuer was established as a joint-stock company through the overall restructuring of Hualan Co., Ltd. On May 19, 2020, Dahua Certified Public Accountants issued the Dahua Audit Report No. [2020] 0010398, confirming that as of April 30, 2020, the net assets of Hualan Co., Ltd. were 1,239.7908 million yuan. On May 19, 2020, China United Assets Appraisal Group issued the Appraisal Report No. [2020] 1078, assessing the net assets of Hualan Co., Ltd. as 1,433.3211 million yuan based on the appraisal benchmark date of April 30, 2020. On May 19, 2020, the board of directors of Hualan Co., Ltd. resolved to legally transform Hualan Co., Ltd. into a joint-stock company. All promoters jointly signed the "Promoter Agreement," agreeing to convert the audited net assets of Hualan Co., Ltd. as of April 30, 2020, amounting to 1,239.7908 million yuan, into 360 million shares at a ratio of 3.4439:1, with a par value of 1 yuan per share. The portion of net assets exceeding the registered capital, 879.7908 million yuan, was recorded as capital reserve. On June 3, 2020, the company held its inaugural meeting and reviewed and approved the relevant proposals for the overall transformation of Hualan Co., Ltd. into a joint-stock company. On June 3, 2020, Dahua Certified Public Accountants issued the Capital Verification Report No. [2020] 000248, confirming that the capital contributions of all promoters for this overall transformation had been fully paid. On June 4, 2020, the company completed the change registration procedures with the Xinxiang Administration for Industry and Commerce and obtained the "Business License" with registration number 91410700782203354G.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Hualan Biological Engineering Co., Ltd. | General Legal Person | 40500.00 | 67.43 |
| 2 | CYBER CREATOR LIMITED | General Legal Person | 5400.00 | 8.99 |
| 3 | Xinxiang Chenyi Qiming Management Consulting Partnership (Limited Partnership) | General Legal Person | 2538.64 | 4.23 |
| 4 | Henan Huaying Enterprise Management Consulting Partnership (Limited Partnership) | General Legal Person | 2395.94 | 3.99 |
| 5 | China Merchants Guozheng Biopharmaceutical Index Securities Investment Fund (LOF) Class A | Fund | 209.51 | 0.35 |
| 6 | Hong Kong Securities Clearing Company Ltd. | Northbound Capital | 208.22 | 0.35 |
| 7 | Southern China Securities 1000 Exchange Traded Open-End Index Securities Investment Fund | Fund | 165.22 | 0.28 |
5. Concept Sectors
- Biological Vaccines
- Hepatitis Concept
- Margin Trading & Securities Lending
- Recently Weak
- Below IPO Price
- ChiNext 300
- ChiNext Pharmaceuticals
- ChiNext Small Cap
Remarks
- Data update date: 2026-01-01
- Data source: Public Market Information